AstraZeneca taps antibody-mining startup Alchemab to dig into prostate cancer
While antibodies have drawn attention lately for fighting infectious diseases like COVID-19, AstraZeneca hopes to wield them against prostate cancer, and it’s starting with a proof-of-concept project with analytics startup Alchemab Therapeutics. The plan: to explore why some people get prostate cancer, but others don’t.